Skip to main content

Advertisement

Table 1 Patient-, tumor-, and treatment-related characteristics

From: Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

   All Patients (n = 44,498) Immunotherapy (n = 5807) Chemotherapy (n = 38,691) p-value
No. % No. % No. %  
Sex Male 24,693 55.5 3031 52.2 21,662 56.0 < 0.001
Female 19,805 44.5 2776 47.8 17,029 44.0  
Age 18–59 13,849 31.1 1947 33.5 11,902 30.8 < 0.001
60–69 15,487 34.8 2060 35.5 13,427 34.7  
70–79 12,224 27.5 1499 25.8 10,725 27.7  
80+ 2938 6.6 301 5.2 2637 6.8  
Comorbidity 0 28,932 65.0 3889 67.0 25,043 64.7 < 0.001
1 11,280 25.3 1456 25.1 9824 25.4  
> 2 4286 9.6 462 8.0 3824 9.9  
Histology Adenocarcinoma 26,202 58.9 4596 79.1 21,606 55.8 < 0.001
Non-adenocarcinoma 18,296 41.1 1211 20.9 17,085 44.2  
Race White 37,293 83.8 4950 85.2 32,343 83.6 < 0.001
Non-white 7205 16.2 857 14.8 6348 16.4  
Insurance Uninsured 1871 4.2 186 3.2 1685 4.4 < 0.001
Insured 42,627 95.8 5621 96.8 37,006 95.6  
Facility Type Academic 14,480 32.5 1913 32.9 12,567 32.5 0.48
Nonacademic 30,018 67.5 3894 67.1 26,124 67.5  
Radiation No Radiation 21,593 48.5 3344 57.6 18,249 47.2 < 0.001
EBRT 20,821 46.8 2235 38.5 18,586 48.0  
SRT 2084 4.7 228 3.9 1856 4.8  
Systemic Agent Multi-agent chemotherapy 38,691 86.9      
Immunotherapy 5807 13.1